## **Special Issue**

# Novel Perspectives on Hypoxia in Cancer

## Message from the Guest Editor

Hypoxia is a complex and ubiquitous feature of nearly all solid cancers that increases the transcriptional activity of the hypoxia-inducible transcription factor HIF-1 which plays a broad role in many features of tumorigenesis, contributing to angiogenesis, alterations in tumor microenvironment, tumor progression and metastasis. Hypoxia negatively influences nearly every form of cancer therapy, including radiotherapy, chemotherapy and immunotherapy. Despite its overall prominence in cancer biology, no standard of care has been established to reduce the impact of hypoxia. This Special Issue of *Cancers* will provide a comprehensive overview of these subjects, with a focus on the development of novel approaches to reduce the impact of hypoxia in human cancers.

#### **Guest Editor**

Prof. Dr. Mark W Dewhirst

Duke Cancer Institute, Duke University, Durham, NC, USA

## Deadline for manuscript submissions

closed (31 July 2021)



## Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/41268

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

## **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

